fda glp-1 compounding crackdown news The is proposing the removal of three drugs from the 503B bulks list of active ingredients that outsourcing facilities can use to make compounded medicines, the agency announced on Thursday May 18, 2026: FDA warns

No compounded oral tablets, drops, or microdose formats are available, and Ozempic and Mounjaro are not on the menu

Virtual marketplace Sesame rolled out a new weight loss program that gives eligible consumers access to compounded semaglutide, an ingredient in blockbuster obesity drugs Wegovy and Ozempic, for $249 a month

Malkowski notes observations of individuals on GLP1 medications demonstrating gut microbiome dysbiosis, reduced diversity, reduced phyla abundance, and key bacteria

[5] Furthermore, the thermic effect of proteinthe energy required to digest and metabolize itis higher (approximately 20-30%) than other macronutrients, potentially supporting metabolic health during weight loss

They will also look for new ways to treat problems within the incretin system